Statins for Treatment of Primary Intracerebral Hemorrhage
Key facts
- Who runs it
- The Second Hospital of Anhui Medical University
- Where
- China22 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 264 people, planned
- Started
- 6 May 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atorvastatin Treatment
- Best Medical Treatment
- Record updated
- 28 July 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT)
- Age 18-80 years
- Hematoma located in the supratentorial region
- Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours
- Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well
- Glasgow Coma Scale (GCS) score ≥9
- Baseline hematoma volume of 5-35 mL
- Signed informed consent obtained
Who cannot take part
- Patients who have undergone or are scheduled for immediate surgical intervention
- Use of oral anticoagulants within 1 month prior to symptom onset
- ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH
- Pre-stroke mRS >1
- Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis
- Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care
- Pregnancy or lactation
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.
The 2 groups in the trial
- Atorvastatin Treatment plus Best Medical TreatmentTreatment being tested
Patients in this group will receive atorvastatin treatment plus best medical treatment.
Treatment: Atorvastatin Treatment and Best Medical Treatment
- Best Medical TreatmentExisting treatment, for comparison
Patients in this group will receive best medical treatments in accordance with the guideline-directed management for ICH.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)
- Criteria questions
- Built from NCT07088250, who can take part
- Record updated
- 28 July 2025